Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib, paclitaxel, and rituximab in R/R DLBCL
NCT04856137Phase 2Not yet recruiting
- Sponsor
- National Health Research Institutes
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ruxolitinib in diffuse large B-cell lymphoma (DLBCL), sponsored by National Health Research Institutes. Planned start May 2021; status: not yet recruiting.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04856137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856137.